We use cookies to improve our website and services. They help us understand how visitors use our website. Some cookies are required for the website to function. These are marked as “essential” in the details.
Cookies by Microsoft Clarity are used for website analytics, heatmaps, and session recordings. They help us understand how visitors interact with our website so we can improve usability and performance.
SynAct Pharma AB (Nasdaq Stockholm: SYNACT) has appointed Ann Kristin Led as Chief Financial Officer (CFO), effective 1 March 2026.
Background across life sciences and capital markets
According to the company, Led is an experienced finance executive with a track record in life sciences, pharmaceuticals, and med-tech. She has held senior positions at MedTrace Pharma, MC2 Therapeutics, and Lundbeck, where she worked on financial strategy and organisational growth. Her experience includes fundraising activities, licensing and transaction processes, and oversight of financial operations.
Finance leadership transition
CEO Jeppe Øvlesen thanked Björn Westberg for his work as CFO over the years and noted Malin Wikstrand’s contribution in the interim CFO role.
Clinical milestones and partnering talks
SynAct expects key clinical data from its Phase 2b ADVANCE study by the end of Q2. The company also cited ongoing strategic discussions with potential partners.
Advertisement
Leading providers in pharma and healthcare marketing
